María Socorro Espuelas Millán-rekin lankidetzan egindako argitalpenak (9)

2022

  1. Repurposing the Antibacterial Agents Peptide 19-4LF and Peptide 19-2.5 for Treatment of Cutaneous Leishmaniasis

    Pharmaceutics, Vol. 14, Núm. 11

2018

  1. Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions

    Journal of Dermatological Science, Vol. 92, Núm. 1, pp. 78-88

2016

  1. Novel heteroaryl selenocyanates and diselenides as potent antileishmanial agents

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 6, pp. 3802-3812

2015

  1. Leishmanicidal activities of novel methylseleno-imidocarbamates

    Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 9, pp. 5705-5713

2014

  1. Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis

    Expert Opinion on Drug Delivery, Vol. 11, Núm. 4, pp. 579-597

  2. Novel hybrid selenosulfonamides as potent antileishmanial agents

    European Journal of Medicinal Chemistry, Vol. 74, pp. 116-123

  3. Thermosensitive hydrogels of poly(methyl vinyl ether-co-maleic anhydride) - Pluronic® F127 copolymers for controlled protein release

    International Journal of Pharmaceutics, Vol. 459, Núm. 1-2, pp. 1-9

  4. Topical treatment of L. major infected BALB/c mice with a novel diselenide chitosan hydrogel formulation

    European Journal of Pharmaceutical Sciences, Vol. 62, pp. 309-316

2012

  1. Innovative lead compounds and formulation strategies as newer kinetoplastid therapies

    Current Medicinal Chemistry, Vol. 19, Núm. 25, pp. 4259-4288